A novel prophylactic vaccine and delivery platform to prevent Clostridium difficile infections

C.艰难梭菌感染（CDI）导致住院患者在接受广谱抗生素治疗后出现严重腹泻。CDI可以用特定的抗生素成功治疗，但10名患者中有3名会再次发生感染和腹泻，平均2名患者会死亡。一种疫苗可以预防CDI，但目前还没有。目前在临床试验中的疫苗使用的是无活性的C。difficile毒素to generate产生a immune免疫response响应but not all patients患者respond响应.两家英国公司Absynth和Prokarium正在合作开发针对CDI的第一种疫苗。该疫苗是基于一种已经在临床试验中测试过的安全活细菌与新型疫苗抗原的结合，这种抗原提供了一种非毒素的方法，具有潜在的更广泛的预防疾病的保护作用。注射到感染部位的疫苗将针对定植的细菌，因此可以预防感染，接种疫苗的人不太可能成为无症状的携带者。在这个英国创新支持的项目之后，这些公司希望获得额外的投资，将疫苗推向临床试验

C. difficile infection (CDI) causes severe diarrhoea in hospital patients after treatment with broad-spectrumantibiotics. CDI can be successfully treated with specific antibiotics, but infection and diarrhoea re-occurs in upto 3 out of 10 patients and on average 2 of these will die. A vaccine could prevent CDI but none is currentlyavailable. The vaccines currently in clinical trials use inactive C. difficile toxins to generate an immune responsebut not all patients respond. Two UK companies, Absynth and Prokarium, are collaborating to create the firstoral vaccine against CDI. The vaccine is based on combining a safe living bacterium already tested in clinicaltrials, with novel vaccine antigens that offer a non-toxin based approach with potentially broader protectionagainst disease. The vaccine delivered to the site of infection, will target the colonising bacteria, so infectioncould be prevented and those vaccinated are unlikely to become asymptomatic carriers. After this Innovate UKsupported project, the companies hope to gain additional investment to progress the vaccine into clinicaltrials